Safety Concerns With Gene Therapies: Barry Byrne, MD, PhD

Video

The director of the Powell Gene Therapy Center at the University of Florida discussed adverse events in gene therapies.

“The field is very focused right now on some of the early safety events because of adverse events in some studies. We think we've learned some important mechanistic underpinnings of those safety events and are hoping that we can employ strategies that block those aspects of systemic gene transfer that may be the cause of safety problems in gene therapy. We need these therapies to be safe and effective because of the need to have these types of therapies available to the broad community.”

Gene therapies are being investigated as potential treatments for many previously incurable diseases, including Pompe disease, but their development is not without its challenges. As more therapies are evaluated, serious adverse events (AEs) that arise from gene therapies are gaining attention. The FDA Cellular, Tissue, and Gene Therapies Advisory Committee met last month to address the unmet need of AEs in gene therapies.

GeneTherapyLive spoke with Barry Byrne, MD, PhD, director of the University of Florida’s Powell Center for Gene Therapy and advisory committee member, to learn more about adverse events associated with gene therapies, including dose limiting toxicities and the need to mitigate adverse events to advance the availability of gene therapies.

REFERENCE
Spark Therapeutics announces first participant dosed in phase 1/2 study of investigational gene therapy for late-onset Pompe disease. News release. Spark Therapeutics. February 1, 2021. https://sparktx.com/press_releases/first-patient-dosed-pompe/
Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Related Content
© 2024 MJH Life Sciences

All rights reserved.